A Phase 1b, Open-label, Multi-center, Single Arm, Dose Finding Study to Assess Safety and Pharmacokinetics of the Oral Combination of Panobinostat and Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera-myelofibrosis (PPV-MF) or Post-essential Thrombocythemia-myelofibrosis (PET-MF)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Oct 2017
At a glance
- Drugs Panobinostat (Primary) ; Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals Corporation
- 13 Oct 2017 Planned End Date changed from 13 Dec 2017 to 12 Dec 2018.
- 13 Oct 2017 Planned primary completion date changed from 13 Dec 2017 to 12 Dec 2018.
- 13 Feb 2017 Planned End Date changed from 1 Dec 2016 to 13 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History